Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641177 | 0.96 | CHRM1 (0.45) | F10CHRM1OPRM1DRD2MDM2 | |
| SCHEMBL641609 | 0.93 | CHRM1 (0.49) | F10CHRM1OPRM1DRD2MDM2 | |
| SCHEMBL641212 | 0.93 | CHRM1 (0.47) | CHRM1OPRM1DRD2MDM2CHRM3 | |
| SCHEMBL639650 | 0.90 | F10 (0.46) | F10CHRM1OPRM1DRD2PLD1 | |
| SCHEMBL641604 | 0.89 | CBX7 (0.43) | F10CHRM1OPRM1 | |
| SCHEMBL642360 | 0.89 | DRD2 (0.47) | CHRM1OPRM1DRD2PLD1CHRM3 | |
| SCHEMBL640811 | 0.89 | F10 (0.47) | F10CHRM1OPRM1PLD1CHRM3 | |
| SCHEMBL640231 | 0.88 | CHRM1 (0.42) | CHRM1OPRM1CHRM3 | |
| SCHEMBL639676 | 0.87 | CHRM1 (0.41) | F10CHRM1OPRM1PLD1CHRM3 | |
| SCHEMBL641143 | 0.87 | F10 (0.44) | F10CHRM1OPRM1PLD1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | F10 276/4885CHRM1 112/4885OPRM1 392/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | F10 276/4885CHRM1 112/4885OPRM1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.